Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FNP-223 in Progressive Supranuclear Palsy
NCT06355531Phase 2Active, not recruiting
- Sponsor
- Ferrer
- Start
- Jul 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of ASN120290 in progressive supranuclear palsy (PSP), sponsored by Ferrer. Started Jul 2024; status: active, not recruiting.
02
Drugs
ASN120290
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT06355531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06355531.